Tarik Asselah, MD, PhD, professor of hepatology at Hôpital Beaujon and the University of Paris-Cité, highlighted alcohol-related liver disease and rare liver conditions as chronically underfunded ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best high short interest stocks with highest upside potential. On ...

EIT Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress ...

Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b ...

With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease ...

Alcohol policy and liver disease were central at this EASL 2026 session. Experts called for stronger labelling and prevention ...

Supplement-induced liver injury is rising as wellness supplement use grows globally. Learn more about the risks highlighted at EASL 2026.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization. Two posters presented at EASL 2026 ...

111,08 111,36 03.06. - Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen ...

This Phase 1 trial built on preclinical data showing that the combination of a FASN inhibitor and resmetirom improved liver histology versus monotherapy through complementary mechanisms of liver fat ...